Carboplatin-induced immune hemolytic anemia.
BACKGROUND
A case of acute hemolysis following therapy with carboplatin, an anticancer chemotherapeutic agent, was investigated. Hemolytic anemia has been associated with cisplatin, a related drug, but not with carboplatin.


METHODS
An 8-year-old boy was treated for an astrocytoma by monthly intravenous injections of carboplatin. Lower back pain was noted after 26 monthly injections, and overt intravascular hemolysis occurred after the 27th injection. The direct antiglobulin test was 4+ with anti-IgG and 1+ with anti-C3d.


RESULTS
Blood samples obtained on Days 28 and 56 after the last injection were tested for carboplatin-dependent antibody. The direct antiglobulin test was 1+ with anti-IgG; the eluate was 1+ with and without carboplatin. The serum indirect antiglobulin test was negative in the absence of carboplatin, 3+ to 4+ in the presence of carboplatin, and 1+ with carboplatin-coated cells. Day 56 serum antibody titer was 64 (agglutination at 37 degrees C), 512 (indirect antiglobulin test) in the presence of carboplatin, and 8 (indirect antiglobulin test) with carboplatin-coated cells.


CONCLUSIONS
The findings indicate a carboplatin-induced antibody reacting in vitro by a complex mechanism combining elements of "immune complex," drug adsorption, and autoantibody mechanisms. Drug-dependent hemolysis is a previously unreported but potentially serious complication of carboplatin therapy.
Marani
T M
TM
Clinical Services, American Red Cross Blood Services, Greater Chesapeake and Potomac Region, Baltimore, Maryland, USA.
Trich
M B
MB
Armstrong
K S
KS
Ness
P M
PM
Smith
J
J
Minniti
C
C
Sandler
S G
SG
D000744:Anemia, Hemolytic, Autoimmune / Q000139:chemically induced* / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D001254:Astrocytoma / Q000188:drug therapy; D001323:Autoantibodies / Q000276:immunology*; D001932:Brain Neoplasms / Q000188:drug therapy; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D002648:Child; D002945:Cisplatin / Q000276:immunology; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D017253:Neurofibromatoses / Q000188:drug therapy
D000970:Antineoplastic Agents; D001323:Autoantibodies; D016190:Carboplatin; D002945:Cisplatin